Previous 10 | Next 10 |
Agenus ( AGEN +8% ) is up on light volume in early trade on the heels of its announcement that the FDA has accepted its IND filing for immuno-oncology (I-O) candidate AGEN2373, triggering a $7.5M milestone payment from collaboration partner Gilead Sciences ( GILD ). More news on: ...
Agenus ( AGEN ) Q2 results : Revenues: $15.7M (-1.3%). More news on: Agenus Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Agenus (NASDAQ: AGEN ): Q2 GAAP EPS of -$0.38 misses by $0.05 . More news on: Agenus Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
LEXINGTON, Mass. , Aug. 8, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1 , and cancer vaccines provided corporate updates and reported financial results for the second quarter of...
LEXINGTON, Mass., Aug. 8, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1 and cancer vaccines, announced today that ...
LEXINGTON, Mass. , Aug. 6, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its second quarter 2019 financial results before the market opens on Thursday, August 8, 2019 . Ag...
Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year test of the top three forensic algorithms used to detect bankruptcy risk, earnings manipulation, and financial irregularities. My forward testing compiles portfolio ...
LEXINGTON, Mass. , July 18, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline of novel clinical and preclinical stage checkpoint antibodies, cell therapies and neoantigen vaccines, today announced the appointment of Don Vidic as Vice ...
In my never-ending search for a biotech that presents asymmetric potential in terms of reward compared to cost, I recently took a closer look at one of my watch list biotechs, Agenus, Inc. ( AGEN ). I found a company that has trudged the long and lonesome road as it continues its quest to brea...
LEXINGTON, Mass. , June 13, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , invites investors and the general public to attend its annual meeting of stoc...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...